Skip to main content
Advertisement
  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center

Advanced Search

Main menu

  • Neurology.org
  • Journals
    • Neurology
    • Clinical Practice
    • Education
    • Genetics
    • Neuroimmunology & Neuroinflammation
  • Online Sections
    • Neurology Video Journal Club
    • Diversity, Equity, & Inclusion (DEI)
    • Innovations in Care Delivery
    • Practice Buzz
    • Practice Current
    • Residents & Fellows
    • Without Borders
  • Collections
    • COVID-19
    • Disputes & Debates
    • Health Disparities
    • Infographics
    • Neurology Future Forecasting Series
    • Null Hypothesis
    • Patient Pages
    • Topics A-Z
    • Translations
  • Podcast
  • CME
  • About
    • About the Journals
    • Contact Us
    • Editorial Board
  • Authors
    • Submit New Manuscript
    • Submit Revised Manuscript
    • Author Center
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

User menu

  • Subscribe
  • My Alerts
  • Log in

Search

  • Advanced search
Neurology
Home
The most widely read and highly cited peer-reviewed neurology journal
  • Subscribe
  • My Alerts
  • Log in
Site Logo
  • Home
  • Latest Articles
  • Current Issue
  • Past Issues
  • Neurology Video Journal Club
  • Residents & Fellows

Share

August 07, 2012; 79 (6) Articles

Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS

S.E. Bushnell, Z. Zhao, C.C. Stebbins, D. Cadavid, A.M. Buko, E.T. Whalley, J.A. Davis, E.M. Versage, J.R. Richert, R.C. Axtell, L. Steinman, R. Medori
First published May 9, 2012, DOI: https://doi.org/10.1212/WNL.0b013e318259e123
S.E. Bushnell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Z. Zhao
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
C.C. Stebbins
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
D. Cadavid
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
A.M. Buko
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E.T. Whalley
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J.A. Davis
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
E.M. Versage
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
J.R. Richert
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R.C. Axtell
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
L. Steinman
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
R. Medori
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Full PDF
Citation
Serum IL-17F does not predict poor response to IM IFNβ-1a in relapsing-remitting MS
S.E. Bushnell, Z. Zhao, C.C. Stebbins, D. Cadavid, A.M. Buko, E.T. Whalley, J.A. Davis, E.M. Versage, J.R. Richert, R.C. Axtell, L. Steinman, R. Medori
Neurology Aug 2012, 79 (6) 531-537; DOI: 10.1212/WNL.0b013e318259e123

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Permissions

Make Comment

See Comments

Downloads
424

Share

  • Article
  • Figures & Data
  • Info & Disclosures
Loading

This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.

Abstract

Objective: There is a significant unmet need for serum biomarkers in relapsing-remitting multiple sclerosis (RRMS) that are predictive of therapeutic response to disease-modifying therapies. Following a recent Stanford study which reported that pretreatment levels of serum interleukin (IL)-17F could predict poor response to interferon-β (IFNβ) therapy, we sought to validate the finding using samples from a large clinical trial.

Methods: The validation cohort included 54 good responders (GR) and 64 poor responders (PR) selected from 762 subjects with RRMS from the IM IFNβ-1a dose comparison study (Avonex study C94-805). Subjects were classified as GR and PR based on the number of relapses, Expanded Disability Status Scale score, and new and enlarging T2 lesions on MRI. Serum samples were assayed for IL-17F using a multiplexed Luminex assay and for IL-17F/F using an ELISA. Replicate aliquots from the Stanford study were also assayed to assure reproducibility of methods.

Results: Median pretreatment and post-treatment serum IL-17F levels were not statistically significantly different between GR and PR, and serum IL-7/IL-17F ratios were also not predictive of response status. Replicate aliquots from the Stanford study showed good correlation to their original cohort (r = 0.77).

Conclusions: We were unable to validate the finding that serum IL-17F is a predictor of PR in a large independent cohort of subjects with RRMS. Differences in patient populations and methodology might explain the failure to validate the results from the Stanford study.

GLOSSARY

EAE=
experimental autoimmune encephalomyelitis;
EDSS=
Expanded Disability Status Scale;
GR=
good responders;
HV=
healthy volunteer;
IFNβ=
interferon-β;
IL=
interleukin;
MS=
multiple sclerosis;
NAb=
neutralizing antibody;
PR=
poor responders;
RRMS=
relapsing-remitting multiple sclerosis;
SLE=
systemic lupus erythematosus

Footnotes

  • Study funding: This study was sponsored by Biogen Idec.

  • Editorial, page 498

  • Supplemental data at www.neurology.org

  • Received October 18, 2011.
  • Accepted January 31, 2012.
  • Copyright © 2012 by AAN Enterprises, Inc.
View Full Text

AAN Members

We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.

Google Safari Microsoft Edge Firefox

Click here to login

AAN Non-Member Subscribers

Click here to login

Purchase access

For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)

Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here 

Purchase
Individual access to articles is available through the Add to Cart option on the article page.  Access for 1 day (from the computer you are currently using) is US$ 39.00.  Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means.  The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use.  Distributing copies (electronic or otherwise) of the article is not allowed.

Letters: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
  • Article
    • Abstract
    • GLOSSARY
    • METHODS
    • RESULTS
    • DISCUSSION
    • AUTHOR CONTRIBUTIONS
    • DISCLOSURE
    • ACKNOWLEDGMENT
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Disclosures
Advertisement

Use of Whole-Genome Sequencing for Mitochondrial Disease Diagnosis

Dr. Robert Pitceathly and Dr. William Macken

► Watch

Related Articles

  • The elusive biomarker for personalized medicine in multiple sclerosisThe search continues
  • Spotlight on the November 20 Issue

Topics Discussed

  • Multiple sclerosis
  • Diagnostic test assessment
  • Prognosis

Alert Me

  • Alert me when eletters are published

Recommended articles

  • Articles
    A composite score to predict short-term disease activity in patients with relapsing-remitting MS
    Maria Pia Sormani, Marco Rovaris, Giancarlo Comi et al.
    Neurology, September 17, 2007
  • Article
    Vitamin D enhances responses to interferon-β in MS
    Xuan Feng, Zhe Wang, Quentin Howlett-Prieto et al.
    Neurology: Neuroimmunology & Neuroinflammation, October 03, 2019
  • Articles
    Increased cerebrospinal fluid concentrations of the chemokine CXCL13 in active MS
    F. Sellebjerg, L. Börnsen, M. Khademi et al.
    Neurology, December 07, 2009
  • Article
    Dysregulation of the IL-23/IL-17 axis and myeloid factors in secondary progressive MS
    Amanda K. Huber, Lu Wang, Peisong Han et al.
    Neurology, September 24, 2014
Neurology: 100 (12)

Articles

  • Ahead of Print
  • Current Issue
  • Past Issues
  • Popular Articles
  • Translations

About

  • About the Journals
  • Ethics Policies
  • Editors & Editorial Board
  • Contact Us
  • Advertise

Submit

  • Author Center
  • Submit a Manuscript
  • Information for Reviewers
  • AAN Guidelines
  • Permissions

Subscribers

  • Subscribe
  • Activate a Subscription
  • Sign up for eAlerts
  • RSS Feed
Site Logo
  • Visit neurology Template on Facebook
  • Follow neurology Template on Twitter
  • Visit Neurology on YouTube
  • Neurology
  • Neurology: Clinical Practice
  • Neurology: Education
  • Neurology: Genetics
  • Neurology: Neuroimmunology & Neuroinflammation
  • AAN.com
  • AANnews
  • Continuum
  • Brain & Life
  • Neurology Today

Wolters Kluwer Logo

Neurology | Print ISSN:0028-3878
Online ISSN:1526-632X

© 2023 American Academy of Neurology

  • Privacy Policy
  • Feedback
  • Advertise